07:00 , Jun 30, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Mycobacterium tuberculosis transmembrane transport protein 3 (MmpL3)

Infectious disease INDICATION: Tuberculosis In vitro, cell culture and mouse studies identified a carboxamide-based MmpL3 inhibitor that could help treat tuberculosis (TB). Chemical synthesis and testing in an M. tuberculosis-infected mammalian cell line of indole-carboxamide...
07:00 , Sep 1, 2014 |  BC Week In Review  |  Company News

Novartis, TB Alliance deal

Novartis granted the alliance exclusive, worldwide rights to the portfolio of preclinical tuberculosis (TB) compounds discovered at the Novartis Institutes for Tropical Diseases (NITD). The portfolio includes a group of indolcarboxamide candidates, including NITD304 ,...
00:35 , Aug 21, 2014 |  BC Extra  |  Company News

TB Alliance gains Novartis tuberculosis portfolio

Novartis AG (NYSE:NVS; SIX:NOVN) granted the Global Alliance for TB Drug Development (TB Alliance) exclusive, worldwide rights to the entire portfolio of preclinical tuberculosis (TB) compounds discovered at the Novartis Institutes for Tropical Diseases (NITD)....
08:00 , Nov 7, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Tuberculosis Mycobacterium tuberculosis transmembrane transport protein 3 (mmpL3) In vitro and mouse studies identified indol-2-carboxamides that could help treat tuberculosis. In vitro, two carboxamide...